International
As death rate slows, U.S. exceeds 600,000 Covid-19 fatalities
The United States on June 14 crossed the grim milestone of 600,000 Covid-19 deaths, according to a Reuters tally, as slowing vaccination rates threaten the Biden administration target of having 70 percent of U.S. adults receive at least one shot and 160..

As death rate slows, U.S. exceeds 600,000 COVID-19 fatalities
June 14, 2021; 8:15 PM EDT
(Reuters; Roshan Abraham, Anurag Maan)
The United States on Monday crossed the grim milestone of 600,000 COVID-19 deaths, according to a Reuters tally, as slowing vaccination rates threaten the Biden administration target of having 70% of U.S. adults receive at least one shot and 160 million fully inoculated by July 4.
The early success of the U.S. vaccine rollout has had a huge impact on the pace of COVID-19 fatalities in the country.
It took 113 days to go from 500,000 total U.S. COVID-19 deaths to 600,000 – the second slowest 100,000-death jump since the pandemic began. The nation went from 400,000 to 500,000 deaths in just 35 days.
“My heart goes out to those who’ve lost a loved one…. We have more work to do to beat this virus and now’s not the time to let our guard down,” said President Joe Biden on the sidelines of NATO meetings in Brussels, Belgium, urging people to get vaccinated.
Lila Blanks holds the casket of her husband, Gregory Blanks, 50, who died of the coronavirus disease (COVID-19), ahead of his funeral in San Felipe, Texas, U.S., January 26, 2021. REUTERS/Callaghan O’Hare/File Photo
The U.S. seven-day COVID-19 death average has fallen by almost 90% from its peak in January. The country reported 18,587 coronavirus-related deaths in May – about 81% less than in January, Reuters data showed.
While the epicenter of the pandemic has shifted to places like Brazil and India in recent months, the United States remains the hardest-hit nation in terms of cumulative deaths.
But the country has so far vaccinated 166 million adults with at least one dose, according to the U.S. Centers for Disease Control and Prevention (CDC), although the rate of shots administered has dropped significantly from a mid-April peak.
The average seven-day COVID-19 hospitalization number has also plummeted since April due to vaccinations. On June 2, total hospitalized patients fell below 20,000 for the first time since June 24, 2020.
However, hospitalization among teenagers has increased as more easily transmitted virus variants began to spread, according to recent CDC data.
The rate of hospitalization due to COVID-19 increased among adolescents aged 12 to 17 in April to 1.3 per 100,000 people from a lower rate in mid-March, the agency reported.
Overall, daily new COVID-19 cases have also been dropping since March, with the country reporting the lowest number of cases per capita in May of this year, according to a Reuters analysis.
With vaccinations down to about 1.10 million doses per day last week – some 67% lower than the highest seven-day rate – the Biden administration and state governors have come up with all manner of incentives to get unvaccinated people to roll up their sleeves. These include free childcare and rides to vaccination centers, extended Friday night hours at pharmacies and the chance to win $1 million or college scholarships in a lottery.
As of Sunday, nearly 52% of the U.S. population has received their first vaccine dose, according to the CDC.
Our Standards: The Thomson Reuters Trust Principles.
International
Three Big Biopharmaceutical Stocks to Buy Due to Product Pipeline
Three big biopharmaceutical stocks to buy are bearing fruit due to their strong product pipelines. The three big biopharmaceutical stocks to buy shine…

Three big biopharmaceutical stocks to buy are bearing fruit due to their strong product pipelines.
The three big biopharmaceutical stocks to buy shine amid their peers even though that sector’s performance has been “underwhelming” compared to the broader market with the S&P 500 up 13.90% vs. a 6.08% drop for the biotech year to date, according to a recent BofA Global Research report. The reasoning is that sector rotation has put biotech at a disadvantage against a better macro-economic scenario of a “soft landing,” according to the report.
The focus for investors interested in exposure to big biopharmaceutical stocks is a company’s strength of “commercial execution,” versus macro risks, BofA wrote in its research note. With third-quarter earnings season about to start, biopharmaceutical companies with promising products should stand out.
Despite market headwinds of ongoing food and energy inflation, an expanding auto strike and diplomatic challenges in the Middle East, Ukraine, Russia and Iran, the market is trading better than most observers would expect, Perry recently wrote to his Cash Machine subscribers. It also explains why investors with a collective $5.5 trillion are content to collect 5%-plus in guaranteed short-term cash instruments and Treasuries, he added.
Paul Dykewicz interviews Cash Machine investment newsletter leader Bryan Perry.
Three Big Biopharmaceutical Stocks to Buy and Why
The three big biopharmaceutical stocks to buy offer both dividends and a chance for capital appreciation. Perry, who currently averages a dividend yield of 10.8% with Cash Machine’s 29 recommendations, recently wrote that investors can take heart that the Personal Consumption Expenditures (PCE) index data released by the U.S. Bureau of Economic Analysis on Sept. 29. The data showed overall inflation dipping below 4% on an annual basis. When excluding volatile food and energy prices, the latest rise in the key inflation gauge of the Federal Reserve was just 0.1%, a 3.9% increase from the same time span last year.
Three Biopharmaceutical Stocks to Buy: Eli Lilly
Indianapolis, Indiana-based Eli Lilly & Co. (NYSE: LLY) is one of three big biopharmaceutical stocks to buy that are buoyed by their product pipelines.
The stock gained the attention of co-editors Mark Skousen, PhD, and Jim Woods of the Fast Money Alert trading service that features recommendations of both stocks and options.
Mark Skousen, head of Five Star Trader and scion of Ben Franklin, talks to Paul Dykewicz.
Lilly makes a diabetes shot called Mounjaro that company management is hoping will gain Food and Drug Administration (FDA) approval later this year as an obesity treatment. Lilly’s leaders also discussed working on a next-generation diabetes and weight-loss drug called Retatrutide.
Strong revenue and earnings growth of LLY, along with the promise of millions in additional revenue each quarter for its next-generation weight-loss drug, has the stock surging. During the past 52 weeks, shares are up 87.40%. Lilly’s price performance puts the company’s shares in the top 2% of all stocks on a relative price strength basis.
As shown by the chart below, LLY shares are on a tear, up some 7.12% in the past month and breaking out to new highs on a bullish cup-with-handle pattern. That performance bests its industry, which is down 1.44% in the last month.
Paul Dykewicz meets with Jim Woods, head of Intelligence Report.
The co-leaders of the Fast Money Alert trading service profited from Lilly last year. the duo produced a 11.06% total return in barely five months on October 17, 2022, after its recommendation on May 16, 2022. Now, they are looking to cash in again.
Chart Courtesy of www.stockcharts.com
BofA recently increased its price objective for Lilly to $700 on the back of its clinical and commercial success, with the bullishness based on tirzepatide’s likely approval in obesity during the fourth quarter this year and the company’s incretin pipeline featuring orforglipron and retatrutide. Plus, Lilly has been putting its cash to work with a slew of mergers and acquisitions (M&A) activity, including acquisitions of Versanis, Sigilon, DICE and POINT Biopharma, which BofA wrote investors seem to view favorably.
Three Big Biopharmaceutical Stocks to Buy: Bristol-Myers Squibb
BofA also has a “Buy” recommendation on Bristol-Myers Squibb (NYSE: BMY), of Princeton, New Jersey. Heading into the third quarter, commercial performance from core products such as Opdivo and Eliquis, as well as nine significant new product launches, likely will be top of mind for most investors, BofA opined.
While solid growth from Opdivo, up 13% year over year (y/y), Eliquis, rising 8% (y/y) and the Big 9 new launches, soaring 80% (y/y), is expected, BofA wrote it will take the company a few more quarters for Camzyos and Sotyktu to reach an inflection point. Further, cell therapy products like Abecma and Breyanzi likely will continue to face headwinds from manufacturing and supply in the third quarter, BofA wrote.
BofA wrote that it continues to view Bristol’s shares as attractive, given its robust new product cycle and reasonable valuation of 8x forward P/E, compared to 16x for its peers. The investment firm reiterated its buy rating and $80 price objective on BMY.
Skousen previously recommended Bristol-Myers Squibb profitably in his TNT Trader service that features both stocks and options. In less than two months after he advised its purchase on December 10, 2019, he told his subscribers to take a profit. His related call option recommendation turned a profit, too.
Chart Courtesy of www.stockcharts.com
Three Biopharmaceutical Stocks to Buy: Merck
BofA wrote the Merck & Co. Inc. (NYSE: MRK), of Rahway, New Jersey, is poised to deliver another solid commercial third quarter, driven by strong growth from core products such as Keytruda and Gardasil. Indeed, BofA wrote it expects robust growth of Keytruda in 3Q, spurred by recent approvals in adjuvant lung, continued market penetration and solid data updates.
The investment firm expects strong demand, aided by increased supply due to new manufacturing capacity in 2023/24. Looking forward, BofA forecast investors likely will focus on FDA approval and launch of sotatercept in the first half of 2024. BofA added that market uptake could be robust, given the close-knitted community and treatment centers.
“Ultimately, we remain bullish on MRK shares, given its strong core business,” BofA wrote in a recent research note.
BofA reiterated its buy rating on Merck and set a price objective of $130 per share.
Chart Courtesy of www.stockcharts.com
Three Biopharmaceutical Stocks to Buy: Stocks or Funds?
Another keen observer of the industry is Bob Carlson, a pension fund chairman who also heads the Retirement Watch investment newsletter that features a variety of portfolios. As a risk-averse pension fund leader, Carlson favors funds to enhance diversification and reduce risk.
“I still believe biotech and pharmaceuticals will do well, though they haven’t done well recently,” Carlson told me. “The companies continue to develop new, innovative products.”
Bob Carlson, head of Retirement Watch, gives an interview to Paul Dykewicz.
For a broad-based exposure to biotechnology, consider the ETF iShares Biotechnology (IBB), Carlson advised. The fund tracks the ICE Biotechnology Index, which is composed of U.S.-listed companies. It owns mostly large and mid-cap companies, though about 20% of the fund is in small and micro-cap firms.
IBB recently had 261 stocks, but 56% of the fund was in the 10 largest positions. Top positions were Amgen, Vertex, Regeneron, Gilead Sciences and Seagen. The turnover rate is only 13%.
The fund lost 13.69% in 2022 and is down 6.68% so far in 2023. It lost 4.51% in the last three months and is up 2.54% over 12 months. The dividend yield is around 0.25%.
Three Biopharmaceutical Stocks to Buy: ETFs Offer Alternative
Investors who want to focus exclusively on pharmaceuticals can consider First Trust Nasdaq Pharmaceuticals (FTXH).
The fund tracks the index in its name. About 55% of the fund is in stocks that Morningstar classifies as either giant or large. The stocks in the ETF also on average sell at lower valuations than other health care companies. Almost all the companies are listed in the United States.
FTXH recently owned 50 stocks, and its 10 largest positions were 56% of the fund. Top holdings were AbbVie, Johnson & Johnson, Merck & Co., Pfizer and Bristol-Myers Squibb. The turnover ratio is 76%.
The fund gained 2.55% in 2022 but is down 4.57% so far in 2023. It slid 0.24% in the last three months but rose 7.07% in the past 12 months. Its dividend yield is around 1.67%.
Three Biopharmaceutical Stocks to Buy: Political Risk
The Hamas attack of Israel that triggered a war and Russia’s sustained invasion of Ukraine remain a big factor in keeping lifting political risk for investors. Political risk could rise further after the Russian Defense Ministry released documents recently indicting its military spending could rise by more than 68% in 2024 to reach $111.15 billion. That amounts to about 6% of Russia’s gross domestic product (GDP), more than the country’s spending on social programs, according to Moscow Times. Russia’s military spending is set to total about three times more than education, environmental protection and health care spending combined.
The three big biopharmaceutical stocks to buy offer the appeal of both income and potential capital appreciation. Dividend-paying biopharmaceutical stocks should have extra staying power for investors willing to buy shares in them.
Paul Dykewicz, www.pauldykewicz.com, is an award-winning journalist who has written for Dow Jones, the Wall Street Journal, Investor’s Business Daily, USA Today, the Journal of Commerce, Crain Communications, Seeking Alpha, Guru Focus and other publications and websites. Paul can be followed on Twitter @PaulDykewicz, and is the editor and a columnist at StockInvestor.com and DividendInvestor.com. He also serves as editorial director of Eagle Financial Publications in Washington, D.C. In that role, he edits monthly investment newsletters, time-sensitive trading alerts, free weekly e-letters and other reports. Previously, Paul served as business editor and a columnist at Baltimore’s Daily Record newspaper and as a reporter at the Baltimore Business Journal. Plus, Paul is the author of an inspirational book, “Holy Smokes! Golden Guidance from Notre Dame’s Championship Chaplain,” with a foreword by former national championship-winning football coach Lou Holtz. The uplifting book is endorsed by Joe Montana, Joe Theismann, Ara Parseghian, “Rocket” Ismail, Reggie Brooks, Dick Vitale and many other sports figures. To buy signed and specially dedicated copies, call 202-677-4457.
The post Three Big Biopharmaceutical Stocks to Buy Due to Product Pipeline appeared first on Stock Investor.
dow jones sp 500 nasdaq stocks federal reserve etf treatment fda therapy gdp iran russia ukraineInternational
Chinese Data Dump Steamrolls Expectations, Setting Victorious Stage For Xi’s BRI Address
Chinese Data Dump Steamrolls Expectations, Setting Victorious Stage For Xi’s BRI Address
With Xi preparing to address delegates from 130 nations…

With Xi preparing to address delegates from 130 nations around the world at the third Belt and Road Initiative Forum, we should not be too surprised if the deluge of Chinese macro data tonight - headlined by Q3 GDP - will beat expectations.
In fact, as Bloomberg's Chang Shu and David Qu noted, China’s recovery could be starting to get some traction, supported by stronger public investment and monetary easing, as weekly activity data rebounded in September...
...and overall China data has surprised more to the upside in recent months (admittedly against very weak expectations)...
However, bear in mind that base effects will dampen the year-on-year readings.
Growth in 2Q23 was flattered by a comparison with a depressed performance in 2Q22 caused by the Zero-COVID lockdowns. That boost will be gone in 3Q23, so most economists will be focused on the QoQ growth.
The Yuan has been relatively stable since the end of Q2, after plunging in Q1 and Q2...
And, despite all the pumping and support, China's Credit Impulse remains negative (for the 5th month in a row) as its real estate market continues to implode sucking up every yuan to fill the hole-filled bucket balance sheet of Chinese citizenry...
Oh and while we are discussing that, China Property Stock gauge plunged to its lowest since 2009...
So, eyes down for a fun night of 'adjustments' from Beijing.
China's GDP growth YoY in Q3 was expected to come in at +4.5% (down from +6.3% in Q2) but most eyes will be focused on the QoQ number (+0.9% exp) due to base effects from the COVID lockdowns.
The headline QoQ GDP printed +1.3% (better than expected).
Helped by a downward revision for Q2 from +0.8% to +0.5%. The headline YoY data beat expectations (+4.9% YoY vs +4.5% exp and +5.2% YTD YoY vs +5.0% YTD YoY exp)...
Industrial Production and Retail Sales beat expectations...
-
*CHINA SEPT. INDUSTRIAL OUTPUT RISES 4.5% Y/Y; EST. 4.4%
-
*CHINA SEPT. RETAIL SALES RISE 5.5% Y/Y; EST. 4.9%
While the data show increasing consumer spending growth, the big downside is that China’s property slump is still deep and ongoing.
-
*CHINA JAN.-SEPT. FIXED INVESTMENT RISES 3.1% Y/Y; EST. 3.2%
-
*CHINA JAN.-SEPT. PROPERTY DEV. INVESTMENT -9.1% Y/Y, EST. -8.9%
Worse still, the area of property sold fell 7.5% in September, lower than -7.1% seen the previous month.
Chinese unemployment miraculously tumbled to 5.0% - the lowest since Oct 2021.
Of course, China continues to hide its youth unemployment rate - after it reached record highs at 21.3% in June.
China's statistics bureau said in the release, overall, China’s economy continued to recover in the first three quarters, laying a “solid foundation” for achieving the full-year development goals. Although, China once again warned of the external environment, saying it is becoming more complex and severe.
Under the hood, the fastest growing retail sales categories relate to vice and virtue.
Tobacco and alcohol sales were up a massive 23.1% year-on-year, a remarkable number (the highest recorded since April 2021). Sports items sales surged 10.7%.
So to sum things up - while investment (especially property) continues to be ugly everything else beat (miraculously)
Michael Hirson of 22V Research says in a note he’s paying most attention to signs of any recovery in household and private sector demand.
“Property sales and related indicators will provide a sense of whether recent easing measures are having an effect preliminary data suggest a pick-up in sales in the largest markets (tier 1 and some tier 2) but one that is thus far limited in its strength and breadth,” he wrote in a note.
“On the consumption side, August showed some improvement in household spending on goods, rather than just services, and it will be important to see whether there are further signs of progress as reflected not only in monthly retail sales but also the quarterly survey of household income and spending.”
Given his thoughts, property sales and investments data were ugly - not a good sign... and on the consumption side, everyone was celebrating their non-job 'job'.
The bottom line from the data - China bottomed... a perfect narrative for Xi.
Government
Pro-Hamas Groups Push Critical Race Theory, Socialism In US
Pro-Hamas Groups Push Critical Race Theory, Socialism In US
Authored by Brad Jones via The Epoch Times (emphasis ours),
A California woman…

Authored by Brad Jones via The Epoch Times (emphasis ours),
A California woman sobbed as she learned her friend’s 19-year-old son was kidnapped by the Hamas terrorist group in Israel.
The next day, on Oct. 12, as news of pro-Palestinian “Day of Resistance” rallies spread across the United States, the woman, who is of Jewish heritage and asked not to be named for fear of reprisal, broke the tragic news: Her friend’s son had been murdered by the terrorists.
The same evening, a group of activists in south Los Angeles staged a protest in solidarity with Palestinians. Two days later, demonstrators again rallied—this time thousands gathering near the Israeli Consulate, at one point shutting down the on- and off-ramps to Wilshire Boulevard from the 405 Freeway.
At the Thursday protest, activists equated the plight of Palestinians to those of “indigenous peoples.” They called the Israeli settlements in the Gaza Strip an “occupation” steeped in racism. They blamed the “capitalist” Jews and white Europeans for the loss of their “indigenous lands” and called for a socialist revolution.
“All resistance to colonial occupation is justified!” shouted one speaker at the event.
Protesters chanted, “From Palestine to Mexico, border walls have got to go,” and “From the river to the sea, Palestine will be free,” among other slogans. They blamed Israeli Prime Minister Benjamin Netanyahu for children killed in retaliatory attacks on Palestine and condemned Zionism, equating it with South African apartheid, fascism, and Nazism.


The protest, at Martin Luther King Boulevard and Figueroa Street, was organized by Unión del Barrio and the Association of La Raza Educators and other left-wing activist groups known for their support of critical race theory, or CRT, and the state-imposed ethnic studies program.
Julia Wallace of the Service Employees International Union (SEIU) spoke out against Zionism. She called for defunding police as “enforcers of capitalism,” saying they should be ousted from the labor union.
Another speaker called for a protest outside the south Los Angeles Police Department station on Oct. 22.
“Let’s take over the police station,” he told the crowd of about 30 supporters.
Meanwhile, an Oct. 16 Reuters/Ipsos poll shows most Americans see Hamas as a terrorist organization, while they view Israel favorably. An Oct. 13 Rasmussen poll found most U.S. voters blame Palestinians for the conflict and agree with calls for the “eradication” of Hamas.
On Oct. 15, thousands of people showing support for Israel rallied in Los Angeles, walking down Pico Boulevard to the Museum of Tolerance.

Support for Israel
Ric Grenell, a Californian and former U.S. Ambassador to Germany who also served as Acting Director of National Intelligence in the Trump administration, condemned the recent attacks on Israeli civilians.
He stated on Twitter on Oct. 13, the Democratic Socialists of America and student groups that support Hamas “are a real threat to America.”
“Voting for Democrats who support Socialists like @DemSocialists and ‘Sanctuary Cities’ policies will absolutely lead to people entering our country freely who haven’t been vetted by U.S. immigration services. ... We must have laws that protect us against people entering the U.S. who support terrorists like Hamas.”
Michael Shellenberger, an author and San-Francisco-based political activist who co-founded the California Peace Coalition and other groups, condemned the terrorist attacks on the Israeli people.
“We unreservedly condemn the atrocities carried out by Hamas and support the right of Israel to defend itself and protect its citizens,” he wrote. “The stories and images of the attack shock the conscience. Nothing on earth could justify such crimes. We condemn those on the radical left who have defended the actions of Hamas terrorists.”
“We are pro-Israel, by which we mean we defend its right to exist and its right to defend itself,” he continued. “At the same time, we urge Israel and its supporters, including the United States, to, in their response, abide by international law in general and the Geneva Convention in particular. That means doing everything possible to avoid killing or injuring civilians in the Gaza Strip.”
Kelly Schenkoske, an independent researcher and education advocate, and a critic of critical race theory being taught in California classrooms, denounced the protests pushing critical ideologies.
“We’re seeing protests at college campuses nationwide in support of Palestine, but this issue does not just reside on our college campuses, it resides in the K-12 sector, especially within ethnic studies,” Ms. Schenkoske said.

The state-imposed ethnic studies curriculum in California is “filled with radical ideology,” she said.
“The same activists demanding safe schools promote antisemitic ethnic studies content aimed at decolonizing education [and] promoting critical consciousness and training in neo-Marxism. We need to defund antisemitism in schools entirely,” she said.
Deborah Fillman, a former teacher and education analyst based in North Carolina, told The Epoch Times that California schools are teaching “lies” as historical information through its ethnic studies programs.
“They’re doing it under the guise of social justice, which is false. There’s no justice that can come from murder. There is no legitimate resistance that comes from the wanton slaughter of innocent civilians,” she said.
“From the river to the sea, Palestine will be free,” is a Hamas slogan that means “all the Jews have to go—the eradication of Israel,” said Ms. Fillman, who is Jewish.
The pro-Palestinian protestors aren’t calling for a two-state solution but are instead supporting Hamas when they chant those words, she said.
“It is literally a war crime—every single thing [Hamas] did—including using their own people as human shields,” Ms. Fillman said.
Colonizer Versus Oppressed
Tammi Rossman-Benjamin, a co-founder and director of the AMCHA Initiative, a non-profit organization that combats antisemitism, told The Epoch Times that proponents of ethnic studies have used the Israeli-Palestinian conflict “as a way to essentially beat up their political enemies.”
The pro-Palestinian protestors are using the tenets of critical race theory to frame the Israeli-Palestinian conflict in terms of the colonizer and the oppressed, she said.
“It’s the whole binary oppressed-oppressor [concept] at the heart of ethnic studies that they’ve expanded to talk about politics and international politics,” she said. “In this case, their political agenda aligns up with Hamas’s political agenda which is to destroy Israel.”
Hamas doesn’t talk about colonialism, she said.
“It talks about Holy War, it talks about jihad,” and it calls for the ethnic cleansing of Jews from what it considers Muslim lands, Ms. Rossman-Benjamin said.
The recent “beheading of babies, rape, kidnapping, and massacres” represent the worst and largest number of atrocities committed against Jews since the World War II Holocaust, she said.
“For Jews, this is really unprecedented in two generations,” she said.
The AMCHA Initiative issued a statement saying it is “shocked and horrified at the gruesome massacre of over 900 Israelis—children, mothers, grandmothers, fathers, entire families—hundreds of them gunned downed at a music festival ... reports of rape and torture, and an estimated over 100 Israelis kidnapped, including children, the elderly, a Holocaust survivor, young women, teenagers, and families.”
The Jewish community in the U.S. is now bracing for more pro-Palestinian protestors across dozens of university campuses expressing support for “this genocidal campaign,” AMCHA stated.
The Harvard Undergraduate Palestine Solidarity Committee and more than 30 other student groups recently signed a statement arguing that Israel’s “apartheid regime” is entirely to blame for the attacks. However, following public backlash, at least five organizations that initially signed the letter withdrew their support.
“We will work hard to expose and combat on-campus supporters and apologists for terror, especially the faculty and departments who provide academic legitimacy for the murder of Jews while disingenuously wrapping themselves in the mantle of academic freedom,” AMCHA stated. “Our hearts are broken, but our resolve is not. We stand united with the Jewish people in Israel and around the world.”
At the University of California—Santa Cruz (UCSC), the Critical Race and Ethnic Studies (CRES) department, which studies “race intersectionality in the context of power,” put out a statement Oct. 11 in support of the Palestinian people.
“In this moment—when we are grieving lives lost, fearing the many more to come, and witnessing Israel once again retaliate against a trapped Palestinian population in Gaza—we want to underscore the need for study,” CRES stated. “What we are witnessing needs to be understood in the context of 75 years of settler colonial displacement, military occupation, and enclosure. As in the past, racialized media coverage dehumanizes Palestinians, delegitimizing their aspirations for freedom from militarism, colonial rule, and incarceration.”
The department claims the world is witnessing “the circulation of technologies that are weaponized against Palestinians first, and, subsequently, our most vulnerable populations in the United States, on our borders and globally,” and cites this as the reason why it supports “the critical study of Zionism.”
The university has received pushback from at least seven members of the faculty, including Ms. Rossman-Benjamin’s husband, Ilan Benjamin, a chemistry professor. On Oct. 4, the group sent a letter to UCSC Chancellor Cynthia Larive expressing “grave concerns” ahead of the inaugural conference of the Institute for the Critical Study of Zionism, held on Oct. 13–14.
Although the conference has been condemned in the Jewish community “for its deeply offensive, antisemitic content and goals,” the letter focuses on the fact the conference is co-sponsored by three academic units at UCSC: the CRES department, the Center for Racial Justice, and the Center for Creative Ecologies, the faculty members wrote.
“While these three units may justify their co-sponsorship as a legitimate expression of academic freedom, we vehemently disagree,” they wrote. “It is an outrage that three departments at a publicly funded university are not only sponsoring a politically motivated and directed conference that limits participation to those who agree with the conference’s antisemitic goals, they are committing their department to embracing these goals, thereby threatening their own faculty and students, and members of the entire campus community. This is not a legitimate expression of academic freedom, but rather an egregious abuse of it.”
-
Uncategorized21 hours ago
Roblox integrates XRP as payment method
-
Uncategorized4 hours ago
Physicists create new form of antenna for radio waves
-
Uncategorized24 hours ago
FTX customers could get $9B shortfall claim payout by mid-2024
-
International10 hours ago
Star Alliance opens new lounge at Paris CDG Airport “carefully curated for a multi-sensorial experience”
-
Uncategorized15 hours ago
A big jump in motor vehicle sales highlights a good September for retail sales
-
Uncategorized16 hours ago
BofA Reports Best Ever Q3 Earnings Even As Held-To-Maturity Losses Soar By $26 BIllion To Record HiIgh
-
Uncategorized15 hours ago
U.S. groundwater is getting saltier—what that means for infrastructure, ecosystems, and human health
-
International16 hours ago
Climate Change Is The Number One Problem Of… No Nation?!